Article
Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.